Previous close | 10.87 |
Open | 10.75 |
Bid | 10.65 x 1100 |
Ask | 10.73 x 800 |
Day's range | 10.63 - 10.87 |
52-week range | 9.60 - 116.80 |
Volume | |
Avg. volume | 92,627 |
Market cap | 222.191M |
Beta (5Y monthly) | 1.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.46 |
Earnings date | 03 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.00 |
SAN JOSE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company’s common stock (the “Revers
SAN JOSE, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock. The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on Wednesday, January 18, 2023, under the existing trading symbol “EAR”
EARGO 7 OFFERS CLARITY MODE, CREATING ITS MOST NATURAL HEARING EXPERIENCE FOR THOSE WITH MILD TO MODERATE HEARING LOSS NEW OTC DEVICE TO BE AVAILABLE IN-STORE THROUGH PARTNERSHIP WITH VICTRA, ONE OF AMERICA’S LARGEST WIRELESS RETAILERSEARGO 5 AND 6 HAVE RECEIVED FDA 510(K) CLEARANCE AS SELF-FITTING HEARING AIDS; EARGO 7 WILL LAUNCH AS EARGO’S THIRD OVER-THE-COUNTER, SELF-FITTING DEVICEEARGO’S RECENT PARTNERSHIP WITH NATIONSBENEFITS CONTINUES TO ADVANCE ITS MISSION TO INCREASE ACCESS TO BETTER HE